Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial.

Background: IPX203 is a novel extended-release, oral carbidopa-levodopa (CD-LD) formulation that provides fast onset and prolonged duration of “On”. In the RISE-PD trial, IPX203 was dosed 2-4 times per day and demonstrated significant increase vs immediate-release (IR) CD-LD in “Good On” time per day and “Good On” time per dose.